ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

In Setback For Generics, Court Overturns FDA.

November 9, 2001

NCI Board of Scientific Advisors also approved a new SBIR grant program for research on circulating cells in cancer detection.

March 26, 2004

Center Directors Solidly opposed To Core grant changes, Ask Upton, NCAB To Find Other Solutions

November 11, 1977

Scatter Radiation from Mammography Presents No Increased Cancer Risk

December 28, 2012

Congress Passes FDA User Fee Bill, Averting Layoffs.

September 21, 2007

Are Lab Budgets Excessive? Views On Intramural Program

April 21, 1995